Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 14365 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke.DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER, BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Deans' stroke musings
Changing stroke rehab and research worldwide now.Time is Brain!Just think of all thetrillions and trillions of neuronsthateach daybecause there areeffective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group. My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html
Sunday, August 13, 2017
Resveratrol Attenuates Neurodegeneration and Improves Neurological Outcomes after Intracerebral Hemorrhage in Mice
Department of Neurosurgery, Medical College of Georgia, Augusta University, Augusta, GA, United States
Intracerebral hemorrhage (ICH) is a devastating type of stroke with a
substantial public health impact. Currently, there is no effective
treatment for ICH. The purpose of the study was to evaluate whether the
post-injury administration of Resveratrol confers neuroprotection in a
pre-clinical model of ICH. To this end, ICH was induced in adult male
CD1 mice by collagenase injection method. Resveratrol (10 mg/kg) or
vehicle was administered at 30 min post-induction of ICH and the
neurobehavioral outcome, neurodegeneration, cerebral edema, hematoma
resolution and neuroinflammation were assessed. The Resveratrol
treatment significantly attenuated acute neurological deficits,
neurodegeneration and cerebral edema after ICH in comparison to vehicle
treated controls. Further, Resveratrol treated mice exhibited improved
hematoma resolution with a concomitant reduction in the expression of
proinflammatory cytokine, IL-1β after ICH. Altogether, the data suggest
the efficacy of post-injury administration of Resveratrol in improving
acute neurological function after ICH.
Intracerebral hemorrhage (ICH) is a catastrophic type of stroke caused by bleeding within the brain parenchyma (Leclerc et al., 2015).
Approximately, 10–15% of strokes are caused by ICH. Despite recent
advances in clinical and preclinical research, the one-month mortality
rate of ICH is 40% and only about 20% of the survivors with spontaneous
ICH regain functional independence at 6 months (Flemming et al., 2001; Qureshi et al., 2001; Gebel et al., 2002; Flaherty et al., 2006; Ke et al., 2015).
Primary as well as secondary brain damage is involved in the
pathological processes of ICH. The primary damage usually occurs within
minutes to hours and is mainly caused by mechanical disruption resulting
from the mass effect of hematoma, whereas the cytotoxicity of blood,
excitotoxicity, oxidative stress, and inflammation together result in
secondary brain damage, causing severe disability or death (Xi et al., 2006; Aronowski and Zhao, 2011).
Notably, there is no effective therapeutic or surgical treatment for
ICH and the current treatment options even in dedicated stroke centers
are limited to supportive care. Therefore, finding new treatment
regimens that could provide safety and neuroprotection to patients
suffering from ICH is critical.
Neurobehavioral outcome (n = 9–13/group) was
estimated by an independent researcher blinded to the experimental
groups using a composite neurological test, as detailed previously by
our laboratory and others (Rosenberg et al., 1990; Clark et al., 1998; King et al., 2011; Sukumari-Ramesh and Alleyne, 2016; Sukumari-Ramesh et al., 2016).
This 24-point scale composite test that determines the sensorimotor
deficits associated with intrastriatal ICH, is comprised of six
neurobehavioral sub-tests (climbing, circling, compulsory circling,
whisker response, bilateral grasp, and beam walking; Rosenberg et al., 1990; Clark et al., 1998; King et al., 2011; Sukumari-Ramesh and Alleyne, 2016; Sukumari-Ramesh et al., 2016).
Briefly, the climbing ability of the mouse was assessed using a
gripping surface kept at 45° angle and the circling behavior was tested
on an open bench top. To assess compulsory circling, mouse was placed on
its front limbs on a bench and held suspended by its tail and the
whisker response was evaluated with a gentle touch to its whisker using a
swab. The bilateral grasp assessed the strength to hold onto a steel
grip-bar with forepaws and the beam walking was graded by evaluating the
ability of a mouse to traverse a narrow beam. Each sub-test was scored
from 0 (performs with no impairment) to 4 (severe impairment) and the
individual subtest scores are provided as Supplementary Data-Table 1.
A composite score was calculated as the sum of the scores on all the
six sub-tests, establishing a maximum neurological deficit score of 24.